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Abstract 
 
Objective 
Tobacco smoking is a risk factor for gastroesophageal reflux, but whether other tobacco 
products increase the risk is unclear. The aim of this study was to investigate if snus 
increases the risk of gastroesophageal reflux symptoms (GERS). 
Material and Methods 
The study was based on the third Nord-Trøndelag health study (HUNT3), a population-based 
study of all adult residents in Nord-Trøndelag County, Norway, performed in 2006−2009. The 
association between self-reported severe heartburn/regurgitation and snus use was 
assessed by logistic regression. 
Results  
Compared to never snus users, daily snus users had a reduced risk of GERS (OR 0.77, 95% CI 
0.64−0.93), while previous snus users and those using <2 boxes of snus/month had an 
increased risk (OR 1.20, 95% CI 1.00−1.46 and 1.41, 95% CI 1.02−1.96, respectively). There 
was no association between age when starting using snus and GERS. Snus users who started 
using snus to quit or cut down on cigarette smoking, who started using both snus and 
cigarettes or cigarettes alone had an increased risk of GERS. Snus users <30 years of age had 
an increased risk of GERS (OR 1.49, 95% CI 1.02−2.16), while those aged between 50−60 and 
60−70 years had a reduced risk (OR 0.67, 95% CI 0.49−0.93 and 0.51, 95% CI 0.28−0.94, 
respectively). 
Conclusions 
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Daily snus users had a reduced risk of GERS. However, previous snus users and subgroups of 
snus users had an increased risk of GERS indicating reverse causality, such that snus use 
could increase the risk of GERS. 
 
Key words 
Health surveys, oral tobacco, smokeless tobacco, snuff
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Text 
 
Introduction 
 
Snus is a form of smokeless tobacco that has been used for decades in the Scandinavian 
countries. It is consumed by placing a portion under the upper lip in front of the gingiva and 
is increasingly popular amongst young people (1). The snus market is rapidly spreading 
worldwide and snus was recently launched in the US (2, 3). Previous studies have estimated 
that around 22% of men and 4% of women are using snus, and the prevalence of women 
using snus is increasing (2, 4, 5). 
The exposure time of snus is higher than for smoking; with an average duration time of 
60−70 minutes per portion, giving twice as large the amount of nicotine (6, 7). It consists of 
tobacco, water, sodium chloride, sodium carbonate, humectants, and flavoring agents, and 
large amounts of these contents are swallowed into the digestive tract (1, 8, 9). 
Gastroesophageal reflux disease (GERD) is caused by abnormal backflow of gastric contents 
into the esophagus, producing symptoms and mucosal damage (10, 11). The main symptoms 
of GERD are heartburn and regurgitation, and the prevalence of GERD in Western adult 
populations is up to 30% (12, 13). GERD is associated with reduced health related quality of 
life (14) and work productivity (15), and an increased risk of esophageal adenocarcinoma 
(16). Genetic predispositions and lifestyle factors, including obesity and tobacco smoking, 
increase the risk of GERD (17). Due to the existing evidence of tobacco smoking as a causal 
factor for GERD, snus has been proposed as a similar risk factor for the development of 
GERD (17-20). A study by Aro et al. found an association between snus use and histological 
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changes in the esophagus associated with GERD (basal cell hyperplasia and elongation of 
papillae) (21). 
In general, the documentation of the health effects of snus is sparse, and the continuous 
product development of snus and changes in its ingredients makes interpretation of old 
research troublesome (9). 
The aim of this study was to investigate if snus is a risk factor for gastroesophageal reflux 
symptoms (GERS), using a large population-based study from Norway. 
 
Methods 
 
Material 
The Nord-Trøndelag health study (HUNT) is an on-going population based cohort study. 
Nord-Trøndelag is a county in the central part of Norway with about 135,000 inhabitants (in 
2014). All residents above 20 years of age were asked to participate in three health surveys; 
HUNT1 (1984—1986), HUNT2 (1995—1997), and HUNT3 (2006—2008) (22). In HUNT1, 
77,212 individuals (89% of the total population) participated and the corresponding numbers 
were 65,237 (70%) and 50,807 (54%) in HUNT2 and HUNT3, respectively. This makes HUNT 
the largest population based study in Norway, and also one of the largest internationally. 
Data on health-related items were gathered through self-reported questionnaires, clinical 
examinations, and blood samples of the participants. 
As snus use was assessed in HUNT3 only, the present study is based on HUNT3. In addition, a 
short questionnaire for non-participants (the QNP) sent out in 2009 to those who did not 
participate in HUNT3 was also included (n=7,591). 
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Assessment of snus use  
In HUNT3 and the QNP, the participants were asked, "Do you use, or have you previously 
used snus?" with the possible answers "no, never", "yes, but I quit", "yes, occasionally", and 
"yes, daily". 
For those "ever" using snus, HUNT3 included four additional questions regarding snus. The 
participants were asked about their consumption of snus per month, at what age they 
started using snus, their motivation to start using snus, and what type of tobacco they 
started with. These additional questions were not included in the QNP. 
 
Assessment of gastroesophageal reflux symptoms 
GERS was assessed with the question "To what degree have you had acid regurgitation or 
heartburn during the last 12 months" with the alternatives "never", "a little", or "much" 
complaint. Previous validations of this question found that 95−98% of those reporting much 
complaint had symptoms at least weekly, thereby fulfilling the Montreal criteria for GERD 
(11, 23, 24). 
Those reporting much complaint were defined as the case group (“Severe GERS”), while 
those reporting never complaint were defined as controls (“No GERS”). Those reporting a 
little complaint were excluded from our analysis. 
 
Assessment of co-variables 
In the present study age, sex, tobacco smoking, body mass index (BMI), and physical exercise 
were taken into consideration as potential confounders. 
The participants were asked, "Do you smoke?" with the alternatives: "no, I have never 
smoked", "no, I quit smoking", "yes, occasionally", or "yes, daily". 
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Trained personnel measured the weight and height of the participants in HUNT3, while 
weight and height were self-reported in the QNP. BMI was calculated as weight (kg)/height 
(m)^2 and categorized into normal weight (<25.0), overweight (25.0−29.9), and obese 
(≥30.0) according to the World Health Organization’s classification. 
Physical exercise was assessed by the question "How often do you exercise?” with the 
options "less than once a week", "once a week", "2−3 times a week", or "nearly every day", 
and further categorized into ≥ or < weekly, based on the self-reported frequency. 
 
Statistical analysis 
The risk of GERS among snus users compared to not snus users in HUNT3/QNP was 
estimated using multivariable logistic regression, reporting odds ratios (ORs) with 95% 
confidence intervals (CIs). We present crude ORs, age and sex adjusted ORs, and fully 
adjusted ORs, including adjustments for age, sex, smoking status, BMI, and physical exercise. 
The additional questions regarding snus were used in separate sub-analyses. As these 
additional questions only were included in HUNT3, the participants in QNP were excluded in 
these sub-analyses. 
We tested the main model for interactions, and based on these results we performed 
analyses stratified by age and smoking status. 
Statistical software: STATA 14.0 (StataCorp LP, College Station, TX) 
 
Informed consent and ethical approval 
All participants in HUNT gave written informed consent on participation that their data could 
be used in future medical research. Ethical approval was obtained from the Regional 
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Committee for Medical and Health Research Ethics (reference: 2012/1290/REK midt) before 
the study was initiated. 
 
Results 
 
In total, 58,634 individuals participated in HUNT3 and the QNP and 2,993 (5.1%) had severe 
GERS (cases) and 26,610 (45.4%) had no GERS (controls; Table I). 
 
Characteristics 
The cases were older than the controls (mean age 54.3 and 50.1 years, respectively). The 
participation rate was higher among women than men, but the proportion of cases was 
higher among men than women (11.8% and 10.8%, respectively). 
Daily snus use was less common among cases than controls (5.4% and 7.3%, respectively). 
On the other hand, previous snus use and occasional snus use were more common among 
cases. The cases using snus were older than the controls using snus (mean age 43.3 and 41.8 
years, respectively). The mean age at the start of their snus use was similar for both groups. 
Snus consumption (boxes per month) was higher for cases than for controls. More cases 
than controls started using snus to quit or cut down on smoking, and more cases than 
controls started with cigarettes first. Compared to the controls, more cases were current or 
previous tobacco smokers, had a higher BMI, and exercised less frequently. 
 
Associations 
Compared to never snus users, daily snus users had a reduced risk of severe GERS; fully 
adjusted OR 0.77 (95% CI 0.64−0.93; Table II). However, previous snus users had increased 
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risk of severe GERS; fully adjusted OR 1.20 (1.00−1.46). Moreover, those using <2 boxes per 
month had increased risk of severe GERS; fully adjusted OR 1.41 (1.02−1.96), while there 
was no statistically significant association between snus use and use of ≥2 boxes of snus per 
month. 
There was no association between age when starting using snus and severe GERS (Table III). 
Compared to those reporting no specific motivation to start using snus, those snus users 
who started using snus to quit or cut down on smoking had an increased risk of severe GERS; 
adjusted OR 1.50 (1.13−1.99) and 1.88 (1.35−2.61), respectively. Snus users, who started 
with both snus and cigarettes, or cigarettes alone, also had an increased risk of severe GERS; 
fully adjusted OR 2.26 (1.17−4.35) and 1.76 (1.30−2.39), respectively. 
Snus use interacted with age and tobacco smoking status. Stratified analyses showed that 
snus users <30 years of age had increased risk of severe GERS; fully adjusted OR 1.49 
(1.02−2.16) (Table IV and Figure), while those between 50−60 and 60−70 years of age had 
reduced risk; fully adjusted OR 0.67 (0.49−0.93) and 0.51 (0.28−0.94), respectively. Snus 
users who never or previously had smoked had a reduced risk of severe GERS; fully adjusted 
OR 0.75 (0.54−1.03) and 0.62 (0.48−0.79), respectively. Moreover, snus users who were 
occasionally or daily smokers seemed to have an increased risk of severe GERS, however, 
this association did not reach statistical significance; fully adjusted OR 1.39 (0.94−2.04) and 
1.12 (0.78−1.61), respectively (Table IV). 
 
Discussion 
 
This large population-based observational study showed that daily snus users had a reduced 
risk of severe GERS compared with not snus users. However, previous snus users and 
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subgroups of snus users had an increased risk of severe GERS: those consuming <2 boxes of 
snus per month, snus users who started with both snus and cigarettes or cigarettes alone, 
snus users who started using snus to quit or cut down cigarette smoking, and snus users <30 
years of age. In snus users the risk of severe GERS was reduced with increasing age. 
The large population-based study design facilitates subgroup analyses and reduces the risk 
of selection bias. However, it is known that those participating in population-based studies 
have higher socioeconomic status compared to those not participating.  As diseases and 
health related risk factors are often related to socioeconomic status, this makes selection 
bias possible (25, 26) and might weaken the external validity of the results. Except for lower 
average income and education, and the lack of a large city, the population in Nord-Trøndelag 
is representative of the Norwegian population at large (27). The extensive questionnaires 
used in HUNT also allowed adjustments for possible confounders of the association between 
snus use and GERS. Alcohol use is associated with snus use and some studies have also 
found an association between alcohol use and reflux, while other studies have not found any 
association (28). In our previous studies on GERS using the HUNT material, alcohol use was 
not associated with reflux (17, 20) and, thus, we have not included alcohol use as a possible 
confounder in this study. All questionnaires used in this study were self-reported. Even if 
self-reported questionnaires are validated (29), we cannot exclude possible information bias 
in our study (30).  
In HUNT, more men than women were using snus, current snus users were younger than not 
snus users, snus use was associated with lower education, higher alcohol consumption, and 
less physical exercise, and smoking rates were lower among daily snus users (2). 
According to the Montreal definition, GERD is "a condition that develops when reflux of 
stomach contents causes troublesome symptoms and/or complications. (…) In population-
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based studies, mild symptoms occurring two or more days a week, or moderate/severe 
symptoms occurring more than one day a week, are often considered troublesome by 
patients" (11). The HUNT study was initiated before the Montreal consensus and did not use 
this definition. However, the question used in HUNT has been validated and these 
validations have shown that participants reporting severe complaints in HUNT have at least 
weekly symptoms (23, 24). 
We have no information available on whether the participants were taking anti-reflux 
medications. This could have reduced the proportion of participants reporting GERS. In 
addition, participants with GERS may also have developed Barrett’s esophagus which has the 
potential to reduce symptoms. However, only a small percentage of the participants are 
expected to develop Barrett’s so this should not have influenced the overall results.  
In this study we hypothesized that snus use would increase the risk of GERS. However, the 
overall result was that snus use seems to protect against GERS. We believe this could be 
explained by reverse causality, meaning that those with severe GERS because of snus stop 
their exposure to snus (20). The results of the subgroup analyses support this assumption. 
Previous snus users developing GERS may have quit using snus as a result of snus inducing 
GERS. This is also supported by the declining trend from high risk of GERS among young snus 
users to low risk with increasing age. This is the opposite of the trend in prevalence of GERS 
seen in the total population (24). If reverse causality is the explanation, our results will 
wrongfully suggest that snus has a protective effect against GERS and persons with a lower 
predisposition of developing GERS will continue using snus. 
If snus increases the risk of GERS, one would presume an increasing prevalence with 
increasing doses; a dose-response relationship. However, in this study we found that those 
using <2 boxes per month were more likely to have GERS than those with a higher 
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consumption. Again, if our theory of reverse causality is true, this may be explained by GERS 
inducing a reduced exposure to snus. One could argue that GERS induced by snus should 
disappear when quitting snus. However, individuals with GERS probably have several risk 
factors, including a genetic predisposition, but snus is maybe one factor which is 
recognizable as a trigger of GERS and probably easier to deal with than other risk factors. So, 
even if snus is stopped and this has an effect on GERS, it is unlikely that this would make all 
the complaints disappear. A previous study on this topic, the Kalixanda study, found 
histological changes associated with GERD in the mucosa of snus users, supporting an 
increased risk of GERS with snus use (21). However, the study did not find any link between 
snus consumption and GERS.  If our findings are not caused by reverse causality, snus may 
indeed have a protective effect against GERS and this makes our results highly controversial. 
In this case, the protective effect of snus could be explained by increased saliva section in 
snus users (31), the relatively high pH (approximately 8.5) (8, 32) or other unknown effects 
of the snus contents on the esophageal or gastric mucosa, e.g. creating a barrier effect or 
reducing acid secretion, respectively. However, these protective effects would likely affect 
all age groups and cannot explain the reduced risk of GERS exclusively seen in the older snus 
users. 
In conclusion, this study found that daily snus users overall had a reduced risk of GERS. 
However, subgroups of snus users had an increased risk of GERS and we propose that the 
overall result could be due to reverse causality and that snus use actually increases the risk 
of GERS. Further research is needed to conclude whether snus use is a risk factor for the 
development of GERS. A study combining a detailed questionnaire on reflux symptoms, anti-
reflux medication and risk factors with objective investigations with endoscopy and pH-
measurements may increase the evidence on this topic. 
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In 2017-2018, HUNT4 will be conducted and the same population as in HUNT3 will be re-
invited to participate. This provides an excellent opportunity to follow snus users 
prospectively and to investigate further whether the reduced risk of GERS seen in this study 
is related to reverse causality or not.
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Tables 
 
Table I. Characteristics of individuals reporting severe GERS (cases) and no GERS 
(controls) in HUNT3/QNP, compared with the total population 
 Cases with 
severe 
GERS 
HUNT3/QN
P 
Controls with 
no GERS 
HUNT3/QNP 
Total population 
HUNT3/QNP 
Number 2,993 
(5.1%) 
26,610 (45.4%) 58,634 (100%) 
Age, years    
 Mean (s.d.) 54.3 (15.0) 50.1 (16.3) 51.8 (16.4) 
 Median (range) 55 (19−98) 50 (19−102) 52 (19−102) 
Sex    
 Women, no. (%) 1,629 (54.4) 15,024 (56.5) 31,563 (53.8) 
 Men, no. (%) 1,364 (45.6) 11,586 (43.5) 27,071 (46.2) 
Snus status    
 Never, no. (%) 2,438 (81.5) 21,935 (82.4) 47,486 (81.0) 
 Previous, no. (%) 163 (5.5) 1,179 (4.4) 2,820 (4.8) 
 Occasionally, no. (%) 101 (3.4) 882 (3.3) 1,998 (3.4) 
 Daily, no. (%) 161 (5.4) 1,943 (7.3) 4,201 (7.2) 
 Missing, no. (%) 130 (4.3) 671 (2.5) 2,129 (3.6) 
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Age snus users, years    
 Mean (s.d.) 43.4  (13.5) 41.8 (15.1) 42.3 (14.6) 
 Median (range) 43 (19−91) 41 (19−98) 42 (19−98) 
Age starting with snus, years    
 Mean (s.d.) 25 (12.3) 24.6 (11.5) 24.4 (11.6) 
 Median (range) 20 (7−70) 20 (8−80) 20 (7−80) 
    Missing, no. (%) 31 (8.3) 142 (4.8) 522 (7.0) 
Snus consumption, 
boxes/month 
   
 0, no. (%) 2,176 (72.7) 17,865 (67.1) 41,575 (70.9) 
 >0<2, no. (%) 47 (1.6) 342 (1.3) 838 (1.4) 
 ≥2<8, no. (%) 215 (7.2) 1,811 (6.8) 4,479 (7.6) 
 ≥8, no. (%) 70 (2.3) 488 (1.8) 1,333 (2.3) 
  Missing, no. (%) 485 (16.2) 6,104 (22.9) 10,409 (17.8) 
Motivation to start using snus    
 None, no. (%) 191 (51.3) 1,809 (61.6) 4,380 (58.3) 
 Quit smoking, no. (%) 101 (27.2) 596 (20.3) 1,664 (22.2) 
 Cut down on smoking, no. (%) 65 (17.5) 308 (10.5) 876 (11.7) 
 Missing, no. (%) 15 (4.0) 222 (7.6) 591 (7.9) 
Tobacco type started with first    
 Snus, no. (%) 72 (19.4) 694 (23.7) 1,748 (23.3) 
 Snus and cigarettes, no. (%) 13 (3.5) 73 (2.5) 209 (2.8) 
 Cigarettes, no. (%) 213 (57.3) 1,214 (41.4) 3,351 (44.6) 
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 Missing, no. (%) 74 (19.9) 954 (33.0) 2,203 (29.3) 
Smoking status    
 Never smokers, no. (%) 977 (32.6) 12,351 (46.4) 24,521 (41.8) 
 Previous smokers, no. (%) 1,176 (39.3) 7,666 (28.8) 18,241 (31.1) 
 Current smokers, no. (%) 768 (25.7) 6,008 (22.6) 14,335 (24.5) 
 Missing, no. (%) 72 (2.4) 585 (2.2) 1,537 (2.6) 
BMI, kg/m2     
 Mean (s.d.) 28.8 (4.5) 26.3 (4.2) 27 (4.4) 
 Median (range) 28 (14−51) 25.8 (12−55) 26.6 (12−56) 
      Missing, no. (%) 28 (0.9) 347 (1.3) 858 (1.5) 
Physical exercise    
 <Weekly, no. (%) 1,284 (42.9) 9,598 (36.1) 22,511 (38.4) 
 ≥Weekly, no. (%) 1,426 (47.6) 15,372 (57.8) 31,737 (54.1) 
 Missing, no. (%) 283 (9.5) 1,640 (6.2) 4,386 (7.5) 
Abbreviations: BMI, body mass index; GERS, gastroesophageal reflux symptoms (self-
reported degree of complaints with heartburn or acid regurgitation during the previous 12 
months); HUNT3/QNP, the third wave of the Nord-Trøndelag health study and the 
questionnaire to non-participants (2006–2009) 
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Table II. The odds ratio (95% confidence interval) of severe GERS 
compared with no GERS, by snus status (HUNT3/QNP) and snus 
consumption (HUNT3 only) 
Snus status Unadjusted Adjusted for 
age and sex 
Fully adjusteda 
  Never Reference Reference Reference 
  Previous 1.24 
(1.05−1.47) 
1.33 
(1.12−1.59) 
1.20 
(1.00−1.46) 
  Occasionally 1.03 
(0.83−1.27) 
1.23 
(0.99−1.53) 
1.21 
(0.96−1.52) 
  Daily 0.75 
(0.63−0.88) 
0.84 
(0.70−0.99) 
0.77 
(0.64−0.93) 
Snus 
consumption, 
boxes/month 
   
  0 Reference Reference Reference 
 <2 1.13 
(0.83−1.54) 
1.33 
(0.98−1.82) 
1.41 
(1.02−1.96) 
 2−8 0.97 
(0.84−1.13) 
1.04 
(0.89−1.21) 
0.93 
(0.78−1.10) 
 >8 1.18 
(0.91−1.52) 
1.34 
(1.03−1.74) 
1.16 
(0.88−1.54) 
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a) Adjusted for age, sex, smoking status, BMI, and physical exercise  
Abbreviations: BMI, body mass index; GERS, gastroesophageal reflux symptoms (self-
reported degree of complaints with heartburn or acid regurgitation during the previous 12 
months); HUNT3/QNP, the third wave of the Nord-Trøndelag health study and the 
questionnaire to non-participants (2006–2009) 
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Table III. The odds ratio (95% confidence interval) of severe GERS compared with no 
GERS, by age starting using snus, motivation to start with snus and type of tobacco 
started with first, in HUNT3 
Age starting with snus Unadjusted Adjusted for sex Fully adjusteda 
<20 Reference Reference Reference 
20−30 1.06 (0.80−1.39) 1.06 (0.81−1.40) 1.06 (0.78−1.44) 
30−40 0.88 (0.61−1.29) 0.88 (0.60−1.28) 0.70 (0.45−1.07) 
40−50 1.28 (0.87−1.89) 1.27 (0.86−1.87) 1.02 (0.66−1.56) 
50−60 1.39 (0.83−2.32) 1.35 (0.81−2.26) 1.02 (0.59−1.79) 
60-70 1.12 (0.44−2.90) 1.09 (0.42−2.82) 1.13 (0.42−3.00) 
≥70 1.42 (0.17−1.90) 1.35 
(0.16−11.30) 
1.91 
(0.22−17.01) 
Motivation to start using 
snus 
Unadjusted Adjusted for 
age and sex 
Fully adjustedb 
  None Reference Reference Reference 
  Quit smoking 1.55 (1.20−1.99) 1.52 (1.17−1.98) 1.50 (1.13−1.99) 
  Cut down smoking 1.93 (1.42−2.61) 1.91 (1.40−2.59) 1.88 (1.35−2.61) 
Type of tobacco started 
with first 
Unadjusted Adjusted for 
age and sex 
Fully adjustedb 
  Snus Reference Reference Reference 
  Snus and cigarettes 1.72 (0.91−3.25) 1.73 (0.92−3.28) 2.26 (1.17−4.35) 
  Cigarettes 1.77 (1.35−2.31) 1.72 (1.30−2.29) 1.76 (1.30−2.39) 
a) Adjusted for sex, smoking status, BMI, and physical exercise 
b) Adjusted for age, sex, BMI and physical exercise 
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Abbreviations: GERS, gastroesophageal reflux symptoms (self-reported degree of complaints 
with heartburn or acid regurgitation during the previous 12 months); HUNT3, the third wave 
of the Nord-Trøndelag health study (2006–2009) 
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Table IV. The odds ratio and (95% confidence interval) of severe GERS compared 
with no GERS among snus users, stratified by age and smoking status, in HUNT3/QNP 
    
Age stratified Unadjusted Adjusted for sex Fully adjusteda 
  <30 1.37 (0.99−1.90) 1.44 (1.02−2.03) 1.49 (1.02−2.16) 
  30<40 0.98 (0.70−1.37) 0.80 (0.56−1.13) 0.74 (0.50−1.08) 
  40<50 1.11 (0.87−1.42) 0.96 (0.75−1.25) 0.96 (0.72−1.26) 
  50<60 0.85 (0.64−1.14) 0.76 (0.56−1.02) 0.67 (0.49−0.93) 
  60<70 0.57 (0.34−0.95) 0.65 (0.39−1.10) 0.51 (0.28−0.94) 
  70<80 0.58 (0.27−1.26) 0.70 (0.32−1.55) 0.58 (0.23−1.46) 
  ≥80 0.80 (0.24−2.66) 0.82 (0.25−2.76) 0.91 (0.21−4.03) 
Stratified by 
smoking status 
Unadjusted Adjusted for age  
and sex 
Fully adjustedb 
  Never 0.62 (0.47−0.83) 0.76 (0.57−1.03) 0.75 (0.54−1.03) 
  Previous 0.60 (0.48−0.75) 0.63 (0.50−0.80) 0.62 (0.48−0.79) 
  Occasionally 1.24 (0.90−1.71) 1.33 (0.93−1.92) 1.39 (0.94−2.04) 
  Daily 1.32 (0.9−1.80) 1.14 (0.82−1.59) 1.12 (0.78−1.61) 
a) Adjusted for sex, smoking status, BMI, and physical exercise  
b) Adjusted for age, sex, BMI, and physical exercise 
Abbreviations: BMI, body mass index; GERS, gastroesophageal reflux symptoms (self-
reported degree of complaints with heartburn or acid regurgitation during the previous 12 
months); HUNT3/QNP, the third wave of the Nord-Trøndelag health study and the 
questionnaire to non-participants (2006–2009) 
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Figure legends 
Figure. The odds ratio (OR) and 95% confidence interval (vertical lines) of severe 
gastroesophageal reflux symptoms (GERS; self-reported degree of complaints with 
heartburn or acid regurgitation during the previous 12 months) compared with no GERS 
among snus users in different age categories in the third wave of the Nord-Trøndelag health 
study (HUNT3) and the questionnaire to non-participants (QNP) performed 2006-2009. 
Adjusted for sex, smoking status, BMI, and physical exercise. 
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